The Association of Physical Activity to Oral Glucose Tolerance Test Outcomes in Multiple Autoantibody Positive Children: The TEDDY Study

Suzanne Bennett Johnson[1], **Roy Tamura**[2], **Kerry L. McIver**[3], **Russell R. Pate**[3], **Kimberly A. Driscoll**[4], **Jessica Melin**[5], **Helena Elding Larsson**[5,6], **Michael J. Haller**[7], **Jimin Yang**[2], **TEDDY Study Group**[8]

[1]Department of Behavioral Sciences and Social Medicine, Florida State University College of Medicine Tallahassee, FL USA.

[2]Health Informatics Institute, University of South Florida, Tampa, FL, USA

[3]Department of Exercise Science, Arnold School of Public Health, University of South Carolina, Columbia, SC USA

[4]Department of Clinical and Health Psychology, School of Public Health and Health Professions, University of Florida, Gainesville, FL USA

[5]Department of Clinical Sciences, Lund University, Malmö, Sweden

[6]Department of Paediatrics, Skane University Hospital, Malmo, Sweden

[7]Department of Pediatrics, College of Medicine, University of Florida, Gainesville, FL USA

[8]Additional member of the TEDDY Study Group and their affiliations are available online in the electronic supplemental materials

Abstract

Objective: To examine the association of physical activity (PA), measured by accelerometry, to hemoglobin AIC (HbA1c) and Oral Glucose Tolerance Test (OGTT) outcomes in children who were multiple persistent confirmed autoantibody positive for type 1 diabetes (T1D).

Methods: The Environmental Determinants of Diabetes in the Young (TEDDY) multinational study followed children from birth. Children   3 years of age who were multiple persistent confirmed autoantibody positive were monitored by OGTTs every 6 months. TEDDY children's

Corresponding author: Suzanne Bennett Johnson, Department of Behavioral Sciences and Social Medicine, Florida State University College of Medicine Tallahassee, FL USA; suzanne.johnson@med.fsu.edu.

PA was measured by accelerometry beginning at 5 years of age. We examined the relationship between moderate plus vigorous (mod+vig) PA, HbA1c, and OGTT in 209 multiple autoantibody children who had both OGTT and PA measurements.

Results: Mod+vig PA was associated with both glucose and C-peptide measures (fasting, 120-minute, and AUC); higher mod+vig PA was associated with a better OGTT response primarily in children with longer duration of multiple autoantibody positivity. Mod+vig PA also interacted with child age; lower mod+vig PA was associated with a greater increase in C-peptide response across age. Mod+vig PA was not related to fasting insulin, HOMA-IR or HbA1c.

Conclusions: The OGTT is the gold standard for diabetes diagnosis and is used to monitor those at high risk for T1D. We found higher levels of mod+vig PA were associated with better OGTT outcomes in children 5 years of age who have been multiple autoantibody positive for longer periods of time. Physical activity should be the focus of future efforts to better understand the determinants of disease progression in high-risk children.

Keywords

physical activity; OGTT; multiple autoantibody positive

Introduction

Physical activity (PA) is associated with insulin sensitivity in both children[1-4] and adults.[5] PA is recommended for people with both type 1 and type 2 diabetes and for those with glucose intolerance but not yet diagnosed with type 2 diabetes.[6-7] The overload hypothesis suggests that both overweight and sedentary behavior may play a role in the development of type 1 diabetes (T1D).[8] However, the possible role of PA in the development of T1D has yet to be determined.

The Environmental Determinants of Diabetes in the Young (TEDDY) study seeks to identify environmental triggers of T1D in genetically at-risk children followed from birth to 15 years of age. The study protocol includes annual PA assessment via accelerometry from 5 to 10 years, with continued annual PA assessments for children positive for T1D-related autoantibodies thereafter. Children 3 years of age who are multiple autoantibody positive are given an oral glucose tolerance test (OGTT) every 6 months.

OGTTs are commonly used to measure possible disease progression in individuals at high risk for T1D.[9-11] However, the possible role of PA to OGTT response in high-risk individuals has not been extensively studied. The average number of minutes engaged in moderate to vigorous (mod+vig) PA using accelerometers was estimated in first degree relatives of individuals with T1D who were given an OGTT.[12] Mod+vig PA was inversely related to both insulin and C-peptide response to the glucose challenge; those with higher mod+vig PA had lower insulin and C-peptide levels at 120 minutes and as measured by area under the curve (AUC).

The purpose of this study was to examine the association of PA, objectively measured by accelerometry, to OGTT response in children who are multiple autoantibody positive for T1D.

The TEDDY Study

Children with T1D-related human leucocyte antigen (HLA) genotypes were identified at birth at three sites in the US (Colorado, Georgia/Florida, Washington) and three sites in Europe (Finland, Germany, Sweden). HLA eligible children were invited to participate in TEDDY, a natural history study seeking to identify environmental triggers of T1D in genetically at-risk children followed for 15 years. Written informed consents were obtained from parents of all participants and the study was approved by each site's institutional review or ethics board. Participating children are regularly tested for diabetes-related autoantibodies, children's height and weight are measured, and other biologic specimens (e.g., nasal swabs, urine, fecal matter) are collected. Questionnaires and interviews with parents assess other environmental exposures (e.g., diet, stress). The TEDDY design and protocol has been extensively described elsewhere.[13-15]

Study Sample

TEDDY children are regularly tested for autoantibodies against insulin (IAA), GAD (GADA) and insulinoma-associated protein 2 (IA-2A). The assay methods have been published elsewhere.[16] Beginning at 3 years of age, children with two or more autoantibodies are placed on an every 6-months OGTT protocol. Beginning at 5 years of age, children's PA is assessed annually using accelerometry until 10 years of age and annually thereafter in all autoantibody positive children. Children are considered persistent confirmed multiple autoantibody positive if they are positive for at least two of three autoantibodies (IAA, GADA, IA-2A) on two consecutive occasions, 3 to 6 months apart at both certified autoantibody testing laboratories. As of February 28 2021, there were 340 children with persistent confirmed multiple autoantibodies with at least one OGTT assessment who had reached the 5-year study window. Of these, 209 also had a PA measurement and are the focus of the current study.

Physical Activity Assessment

Annually, starting from the 5-year study clinic visit, children were asked to wear an ActiGraph accelerometer (model GT3X+, Fort Walton Beach FL) around their waist, during all waking hours, exclusive of water activities, for at least 7 days. Days on which a child had 8+ hours of wear time were considered valid and children had to have at least 3 valid days to be included in the analysis. Data were averaged across days and age-specific cut-points[17-18] were used to determine the average amount of time a child spent in light, moderate, and vigorous PA. The current analysis focused on moderate to vigorous (mod+vig) PA. A subsequent analysis using Total PA did not improve the analytic models and is not presented here.

Oral Glucose Tolerance Test and Measurement of Hemoglobin A1c

The TEDDY protocol includes an OGTT every 6 months for multiple autoantibody children ≥ 3 years of age. Children are asked to come in fasting and to consume an oral glucose dose of 1.75 g/kg body weight (to a maximum of 75 grams) in a solution of flavored water within 5 minutes. Before 2016, the TEDDY protocol used a two-time point OGTT (0 and 120 minutes). A protocol change occurred in March 2016, when the six-time point (−10, 0,

30, 60, 90, 120) OGTT was recommended. However, families were permitted to complete a two-time point protocol instead of the six-time point protocol and many did. The two-time point protocol consists of a venous glucose sample at time 0 and 120 minutes; a capillary glucose is permitted at 120 minutes. Available samples permitted analysis of fasting glucose, fasting insulin, fasting C-peptide and 120-minute glucose and glucose area under the curve (AUC). Insulin resistance was measured by homeostasis model assessment (HOMA-IR) using fasting glucose and fasting insulin.[19] Sufficient venous samples were available to measure 120-minute C-peptide in 164 children and C-peptide AUC in 162 children. There were insufficient venous samples to measure 120-minute insulin or insulin AUC. Samples were sent to a central TEDDY OGTT laboratory for processing.

A whole blood sample for HbA1c assay is collected at each clinic visit for all children who have tested positive for at least one autoantibody at the 9-month visit or later and sent to the TEDDY HbA1c measurement laboratory. This analysis used the HbA1c measurement collected at the same time as the OGTT.

Data Analysis

Each PA assessment was assigned to the OGTT visit closest in time (mean of 10 days, median 1 day a part). Since OGTT measures were collected at a greater frequency than PA, we imputed PA for certain visits that had an OGTT but were missing a PA record. However, imputation was limited to those children who had at least two PA measurement time points and the imputation was only done between those two time points. The imputation was done linearly for each category of activity (light, moderate, vigorous) as a function of time between the two PA measurements. No imputation was conducted for children with only a single PA measurement time point nor before the first PA measurement time point or after the last PA measurement time point. Imputation was possible for 110 children. The mean number of PA/OGTT observations per child was 2.4 with a range from 1-9.

Linear mixed effect models for longitudinal data were used to test for the association of mod+vig PA as a time-dependent variable with the longitudinal study outcomes: Fasting Glucose, 120-minute Glucose, Glucose AUC, HbA1c, Fasting Insulin, HOMA-IR, Fasting C-peptide, 120-minute C-peptide, and C-peptide AUC. Fixed covariates included: country, sex, and HLA (DR3/4: yes vs no). Time-dependent covariates included: BMIz score, child age, duration since the child became persistent confirmed multiple autoantibody positive, and average accelerometer wear time. Child age and duration since the child became persistent confirmed multiple autoantibody positive were considered to vary randomly across subjects. Possible interactions between mod+vig PA and the study covariates were explored.

Results

The characteristics of the sample of persistent confirmed multiple autoantibody positive children who have reached the 5-year study window and who have at least one OGTT as well as the subsample of these children with both an OGTT and a PA assessment are shown in Table 1. The groups are similar, suggesting the OGTT/PA subsample is representative of the larger sample of multiple autoantibody children at least 5 years of age in TEDDY.

The descriptive statistics for the PA measures and study outcome measures for our targeted group of 209 children at the time of their first PA assessment associated with an OGTT are provided in Table 2. Children spent most of their time in sedentary (Mean = 54.3% of wear time) or light activity (Mean = 35.7% of wear time) and little in vigorous activity (Mean = 1% of wear time). On average, they spent 101 minutes per day in mod+vig PA (Mean = 10.0% of wear time). However, there was considerable variability across children. The sample means for glucose and insulin/C-peptide OGTT outcomes and HbA1c were within the normal reference ranges.[20-22] However, there was considerable variability across the sample in both glucose and insulin-related study outcomes.

Correlations between the study outcome measures showed that fasting Glucose correlated as well with the fasting insulin measures (Fasting Insulin, Fasting C-peptide, HOMA-IR) as it did with Glucose AUC (Table 3). HOMA-IR and Fasting insulin were extremely highly correlated in this sample (r = 0.99). As expected, 120-minute Glucose was highly correlated with Glucose AUC (r = 0.82) and 120-minute C-Peptide was highly correlated with C-peptide AUC (r = 0.90). Glucose AUC and C-peptide AUC were moderately related (r = 0.55). In contrast, HbA1c only correlated with the other glucose measures.

Table 4 provides the results of the mixed models testing the association of mod+vig PA to the glucose-related outcomes. Significant covariates included Country (Fasting Glucose only), BMIz score (Fasting Glucose only), and Child Age (Fasting Glucose and Glucose AUC). Duration of Multiple Autoantibody Positivity was significant in all models but interacted with mod+vig PA in its association with Fasting Glucose, 120 Minute Glucose and Glucose AUC; higher mod+vig PA was associated with lower glucose levels in children who had been multiple antibody positive for longer periods of time. Figure 1a illustrates the predicted Glucose AUC for children at age 8 who vary in both mod+vig PA and duration of multiple autoantibody positivity. For children who had been multiple autoantibody positive for only 1 year, there was little difference in Glucose AUC between those with low (30 minutes) versus high (120 minutes) mod+vig PA. In contrast, for children who had been multiple autoantibody positive for 5 years, Glucose AUC was significantly lower for those with high (120 minute) compared to those with low (30 minute) mod+vig PA. Also noteworthy is the higher Glucose AUC in children with 5 years multiple autoantibody duration compared to children with 1 year multiple autoantibody duration for those with low (30 minute) mod+vig PA. This difference was far less for children with high (120 minute) mod+vig PA.

Mod+vig PA was not related to HbA1c in the study sample. In fact, the only variable associated with HbA1c was Duration of Multiple Autoantibody Positivity; the longer the duration, the higher the HbA1c.

Table 5 provides the results of the mixed models testing the association of mod+vig PA to the insulin-related outcomes. BMIz score was a significant covariate in all models; higher BMIz scores were associated with higher Fasting Insulin, HOMA-IR, Fasting C-peptide, 120-minute C-peptide and C-peptide AUC. Longer duration of Multiple Autoantibody Positivity was associated with lower 120-minute C-peptide and lower C-peptide AUC. However, Duration of Multiple Autoantibody Positivity interacted with mod+vig PA;

the difference in C-peptide response between children with short versus long multiple autoantibody duration was seen primarily in children with low mod+vig PA. This effect is illustrated in Figure 1b. For children with 1 year multiple autoantibody duration, high (120 minute) mod+vig PA was associated with lower C-peptide AUC compared to low (30 minute) mod+vig PA. This was no longer the case for children who had been multiple autoantibody positive for 5 years. Noteworthy is the lower C-peptide AUC in the those with low (30 min) mod+vig PA at 5 years multiple autoantibody duration compared to 1 year. For this low mod+vig PA group, there were marked differences in both Glucose and C-peptide AUC at 5 years multiple autoantibody duration compared to 1 year; Glucose AUC is higher while C-peptide AUC is lower. These marked differences were not seen in those with high (120 minute) mod+vig PA at 1 versus 5 multiple autoantibody duration (see Figure 1a and 1b).

Child age was also a significant covariate in all models with insulin-related outcomes. However, child age also interacted with mod+vig PA in its association with the three C-peptide measures; the association of higher mod+vig PA with lower C-peptide levels was seen primarily in older children. Figure 2 illustrates this interaction for children at 5 and 10 years of age who vary in time spent in low (30 min) vs high (120 min) mod+vig PA. At child-age 5 years, there were no differences in C-peptide AUC in those with low (30 minute) versus high (120 minute) mod+vig PA. As expected, C-peptide AUC increased for all children as they become older. However, this effect was most marked in children who had low (30 minute) mod+vig PA.

Mod+vig PA was not related to Fasting Insulin or HOMA-IR although both were associated with child age and BMIz score; older age and higher BMIz scores were associated with higher Fasting Insulin and HOMA-IR.

In subsequent sensitivity tests, we considered the following alternative analyses: 1) only the observed PA visits were included and no imputation was done, 2) the duration of autoantibody positivity was changed from the start of the second antibody to the start of the first antibody, and 3) Sex and HLA were removed from the model. For all three sensitivity analyses, the results did not change appreciably except that when only observed PA data were included, standard errors were increased and significance levels decreased, supporting the use of imputed PA data. Although country was not a significant factor in any of the analyses except for Fasting Glucose – where Finland and Sweden had higher Fasting Glucose than the US, we reran the models for Europe and the US separately. The findings were similar although the significance levels were reduced due to the decrease in power associated with reduced sample sizes; we found no evidence of differential effects for Europe versus the US.

Discussion

In this sample of multiple autoantibody positive children, mod+vig PA was associated with lower fasting glucose, lower 120-minute glucose and lower glucose AUC in those who had been multiple autoantibody positive for longer periods of time. Our findings suggest that the association of mod+vig PA to glucose outcomes (fasting glucose, 120-minute glucose,

glucose AUC) may be stronger in multiple autoantibody children than antibody negative first-degree relatives or those who are not at risk for T1D. The fact that the association was strongest in those who had been multiple autoantibody positive for longer periods of time suggests that PA might contribute to slowing the disease progression in at least some very high-risk children. However, we cannot conclude such a causal role for PA based on the correlational analyses presented herein. Our findings are novel and appear different from other studies of healthy school-aged children that found no association between PA measured by accelerometry and fasting glucose (Brage et al, 2004; Bailey et al, 2013, Ahassan et al, 2008,Strizich et al 2018; Carson et al 2013, 2019; Jago et al 2008, Haapala et al 2020). The only study using accelerometry with children at risk for T1D, defined by their relationship to a first degree relative with the disease, also did not find an association between PA and fasting glucose (Ungethum et al 2019). That study also did not find any association between PA and 120-minute glucose or glucose AUC.

While prior studies of healthy school-age children have not found an association between PA and fasting glucose, associations between PA and fasting insulin, or between PA and HOMA-IR, are common;[3,23-32] higher PA is associated with lower fasting insulin or HOMA-IR. In our study, mod+vig PA was not related to fasting insulin or HOMA-IR but was related to fasting C-peptide, 120-minute C-peptide, and C-peptide AUC; particularly in older children, higher mod+vig PA was associated with lower C-peptide levels. Ungethum et al (2019) study of 9-14 year old children who were offspring or siblings of patients with T1D also did not find an association between PA and fasting insulin or HOMA-IR.[12] However, consistent with our results, they found 120-minute C-peptide as well as C-peptide AUC were related to PA. C-peptide is considered to be a better measure of beta cell function than insulin;[33] our findings support the greater sensitivity of C-peptide over insulin as a measurement strategy. In fact, when HOMA-IR was recalculated using C-peptide instead of insulin,[34] significant mod+vig PA findings emerged, similar to those found for fasting C-peptide (data not shown).

Children are known to decrease PA as they grow older.[17,27,35] Aging is also associated with an increase in insulin resistance.[36] In our high-risk sample, higher mod+vig PA was associated with lower fasting C-peptide and a better response to the OGTT in older children. These findings suggest that children who maintain higher mod+vig PA as they grow older, may be able to reduce age-related increases in insulin resistance, reducing stress on the pancreatic beta cells. Because our sample was limited to multiple autoantibody children we do not know if this association occurs in most children or is limited to those at very high-risk for T1D.

Mod+vig PA was also found to interact with duration of autoantibody positivity in its association with 120-min C-peptide and C-peptide AUC. In our sample, longer duration of multiple autoantibody positivity was strongly associated with a decline in C-peptide response to the OGTT in those with low mod+vig PA. In the healthy child, the increased insulin resistance associated with normal aging is managed by an increase in insulin production. However, in individuals with autoimmune destruction of beta cells in the pancreas, at some point the pancreas is unable to meet these demands and blood glucose rises in response. Our findings suggest -but certainly do not prove- that PA may slow or

delay this process. The consistent association of mod+vig PA with both Glucose AUC and C-peptide AUC in individuals with long multiple autoantibody duration is intriguing and warrants further study.

The OGTT is considered the gold standard for diagnosis of diabetes and is commonly used to monitor those at risk for the disease. Both glucose and C-peptide measures have proved useful in predicting T1D onset in autoantibody positive individuals,[9-11] highlighting the importance of associations between mod+vig PA and fasting glucose, 120-minute glucose, glucose AUC, and fasting C-peptide, 120-minute C-peptide, and C-peptide AUC as reported herein. We also confirmed the association of both child age and BMIz score to C-peptide results, supporting prior work suggesting that any effort to identify C-peptide cut-points to classify individuals as having loss of beta-cell function must take these factors into account.[36]

In these children at high risk for T1D, mod+vig PA was not related to HbA1c. In fact, the only variable associated with HbA1c was duration of multiple autoantibody positivity; longer duration was associated with higher HbA1c. Compared to glucose and C-peptide measures in response to the OGTT, HbA1c may be a less sensitive predictor of T1D in high-risk subjects.[10]

Study strengths include the use of an objective measure of PA – accelerometry – in a very high-risk sample of multiple autoantibody children monitored by OGTT across time. To our knowledge no other published study has evaluated the potential role of PA in such high-risk children. We acknowledge that accelerometry is not a perfect measure of PA since certain activities are precluded (e.g. water sports). Further, the 3-7 day accelerometry annual data collection used in this study represents a limited sampling of the child's overall PA. Other study limitations include the sample's restriction to children 5 years of age or older and the fact that blood sampling limitations did not permit 120-minute C-peptide or C-peptide AUC to be measured in all study children. However, significant findings emerged in the analyses of these measures despite limited sampling of PA and the reduced sample size.

Although multiple autoantibody children are at very high risk for T1D, the time between becoming multiple autoantibody positive and diagnosis with T1D is highly variable. Identifying factors that contribute to delay or rapid progression to disease diagnosis is critical. The results reported here suggest PA may be one factor worthy of consideration in future efforts to better understand the determinants of disease progression in high-risk children. Our next step in the TEDDY study is to examine the extent to which PA is associated with progression to clinical disease in this high risk population.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

The TEDDY Study Group

Colorado Clinical Center: Marian Rewers, M.D., Ph.D., pI[1,4,6,9,10], Aaron Barbour, Kimberly Bautista[11], Judith Baxter[8,911], Daniel Felipe-Morales, Brigitte I. Frohnert, M.D.[2,13], Marisa Stahl, M.D.[12], Patricia Gesualdo[2,6,11,13], Michelle Hoffman[11,12,13], Rachel Karban[11], Edwin Liu, M.D.[12], Alondra Munoz, Jill Norris, Ph.D.[2,3,11], Holly O'Donnell, Ph.D.[8], Stesha Peacock, Hanan Shorrosh, Andrea Steck, M.D.[3,13], Megan Stern[11], Kathleen Waugh[6,7,11]. University of Colorado, Anschutz Medical Campus, Barbara Davis Center for Childhood Diabetes.

Finland Clinical Center: Jorma Toppari, M.D., Ph.D., PI[¥^1,4,10,13], Olli G. Simell, M.D., Ph.D., Annika Adamsson, Ph.D.[^11], Sanna-Mari Aaltonen[^], Suvi Ahonen[*±§], Mari Åkerlund[*±§], Leena Hakola[*±], Anne Hekkala, M.D.[μ¤], Henna Holappa[μ¤], Heikki Hyöty, M.D., Ph.D.[*±6], Anni Ikonen[μ¤], Jorma Ilonen, M.D., Ph.D.[¥¶3], Sanna Jokipuu[^], Leena Karlsson[^], Jukka Kero M.D., Ph.D.[¥^3, 13], Jaakko J. Koskenniemi M.D., Ph.D.[¥^], Miia Kähönen[μ¤11,13], Mikael Knip, M.D., Ph.D.[*±], Minna-Liisa Koivikko[μ¤], Katja Kokkonen[*±], Merja Koskinen[*±], Mirva Koreasalo[*±§2], Kalle Kurppa, M.D., Ph.D.[*±12], Salla Kuusela, M.D.[* ±], Jarita Kytölä[*±], Jutta Laiho, Ph.D.[*6], Tiina Latva-aho[μ¤], Laura Leppänen[^], Katri Lindfors, Ph.D.[*12], Maria Lönnrot, M.D., Ph.D.[*±6], Elina Mäntymäki[^], Markus Mattila[*±], Maija Miettinen[§2], Katja Multasuo[μ¤], Teija Mykkänen[μ¤], Tiina Niininen[±*11], Sari Niinistö[§2], Mia Nyblom[*±], Sami Oikarinen, Ph.D.[*±6], Paula Ollikainen[μ¤], Zhian Othmani[¥], Sirpa Pohjola [μ¤], Jenna Rautanen[±§], Anne Riikonen[*±§2], Minna Romo[^], Satu Simell, M.D., Ph.D.[¥12], Päivi Tossavainen, M.D.[μ¤], Mari Vähä-Mäkilä[¥], Eeva Varjonen[^11], Riitta Veijola, M.D., Ph.D.[μ¤13], Irene Viinikangas[μ¤], Suvi M. Virtanen, M.D., Ph.D.[*±§2]. [¥]University of Turku, [*]Tampere University, [μ]University of Oulu, [^]Turku University Hospital, Hospital District of Southwest Finland, [±]Tampere University Hospital, [¤]Oulu University Hospital, [§]Finnish Institute for Health and Welfare, Finland, [¶]University of Kuopio.

Georgia/Florida Clinical Center: Jin-Xiong She, Ph.D., PI[1,3,4,10], Desmond Schatz, M.D.[*4,7,8], Diane Hopkins[11], Leigh Steed[11,12,13], Jennifer Bryant[11], Katherine Silvis[2], Michael Haller, M.D.[*13], Melissa Gardiner[11], Richard McIndoe, Ph.D., Ashok Sharma, Stephen W. Anderson, M.D.[^], Laura Jacobsen, M.D.[*13], John Marks, DHSc.[*11,13], P.D. Towe[*]. Center for Biotechnology and Genomic Medicine, Augusta University. [*]University of Florida, Pediatric Endocrinology. [^]Pediatric Endocrine Associates, Atlanta.

Germany Clinical Center: Anette G. Ziegler, M.D., PI[1,3,4,10], Ezio Bonifacio Ph.D.[*], Cigdem Gezginci, Anja Heublein, Eva Hohoff[¥2], Sandra Hummel, Ph.D.[2], Annette Knopff[7],

Charlotte Koch, Sibylle Koletzko, M.D.[¶12], Claudia Ramminger[11], Roswith Roth, Ph.D.[8], Jennifer Schmidt, Marlon Scholz, Joanna Stock[8,11,13], Katharina Warncke, M.D.[13], Lorena Wendel, Christiane Winkler, Ph.D.[2,11]. Forschergruppe Diabetes e.V. and Institute of Diabetes Research, Helmholtz Zentrum München, Forschergruppe Diabetes, and Klinikum rechts der Isar, Technische Universität München. *Center for Regenerative Therapies, TU Dresden, ¶Dr. von Hauner Children's Hospital, Department of Gastroenterology, Ludwig Maximillians University Munich, ¥University of Bonn, Department of Nutritional Epidemiology.

Sweden Clinical Center: Åke Lernmark, Ph.D., PI[1,3,4,5,6,8,9,10], Daniel Agardh, M.D., Ph.D.[6,12], Carin Andrén Aronsson, Ph.D.[2,11,12], Rasmus Bennet, Corrado Cilio, Ph.D., M.D.[6], Susanne Dahlberg, Ulla Fält, Malin Goldman Tsubarah, Emelie Ericson-Hallström, Lina Fransson, Thomas Gard, Emina Halilovic, Gunilla Holmén, Susanne Hyberg, Berglind Jonsdottir, M.D., Ph.D.[11], Naghmeh Karimi, Helena Elding Larsson, M.D., Ph.D.[6,13], Marielle Lindström, Markus Lundgren, M.D., Ph.D.[13], Marlena Maziarz, Ph.D., Maria Månsson Martinez, Jessica Melin[11], Zeliha Mestan, Caroline Nilsson, Yohanna Nordh, Kobra Rahmati, Anita Ramelius, Falastin Salami, Anette Sjöberg, Carina Törn, Ph.D.[3], Ulrika Ulvenhag, Terese Wiktorsson, Åsa Wimar[13]. Lund University.

Washington Clinical Center: William A. Hagopian, M.D., Ph.D., PI[1,3,4,6,7,10,12,13], Michael Killian[6,7,11,12], Claire Cowen Crouch[11,13], Jennifer Skidmore[2], Luka-Sophia Bowen, Mikeil Metcalf, Arlene Meyer, Jocelyn Meyer, Denise Mulenga[11], Nole Powell, Jared Radtke, Shreya Roy, Davey Schmitt, Preston Tucker. Pacific Northwest Research Institute.

Pennsylvania Satellite Center: Dorothy Becker, M.D., Margaret Franciscus, MaryEllen Dalmagro-Elias Smith[2], Ashi Daftary, M.D., Mary Beth Klein, Chrystal Yates. Children's Hospital of Pittsburgh of UPMC.

Data Coordinating Center: Jeffrey P. Krischer, Ph.D., PI[1,4,5,9,10], Rajesh Adusumali, Sarah Austin-Gonzalez, Maryouri Avendano, Sandra Baethke, Brant Burkhardt, Ph.D.[6], Martha Butterworth[2], Nicholas Cadigan, Joanna Clasen, Kevin Counts, Laura Gandolfo, Jennifer Garmeson, Veena Gowda, Christina Karges, Shu Liu, Xiang Liu, Ph.D.[2,3,8,13], Kristian Lynch, Ph.D. [6,8], Jamie Malloy, Lazarus Mramba, Ph.D.[2], Cristina McCarthy[11], Jose Moreno, Hemang M. Parikh, Ph.D.[3,8], Cassandra Remedios, Chris Shaffer, Susan Smith[11], Noah Sulman, Ph.D., Roy Tamura, Ph.D.[1,2,11,12,13], Dena Tewey, Michael Toth, Ulla Uusitalo, Ph.D.[2], Kendra Vehik, Ph.D.[4,5,6,8,13], Ponni Vijayakandipan, Melissa Wroble, Jimin Yang, Ph.D., R.D.[2], Kenneth Young, Ph.D. *Past staff: Michael Abbondondolo, Lori Ballard, Rasheedah Brown, David Cuthbertson, Stephen Dankyi, Christopher Eberhard, Steven Fiske, David Hadley, Ph.D., Kathleen Heyman, Belinda Hsiao, Francisco Perez Laras, Hye-Seung Lee, Ph.D., Qian Li, Ph.D., Colleen Maguire, Wendy McLeod, Aubrie Merrell, Steven Meulemans, Ryan Quigley, Laura Smith, Ph.D..* University of South Florida.

Project scientist: Beena Akolkar, Ph.D.[1,3,4,5,6,7,9,10]. National Institutes of Diabetes and Digestive and Kidney Diseases.

Autoantibody Reference Laboratories: Liping Yu, M.D.[^,5], Dongmei Miao, M.D.[^], Kathleen Gillespie*[5], Kyla Chandler*, Ilana Kelland*, Yassin Ben Khoud*, Matthew Randell*. [^]Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, *Bristol Medical School, University of Bristol, UK.

HLA Reference Laboratory: William Hagopian[3], M.D., Ph.D., Jared Radtke, Preston Tucker. Pacific Northwest Research Institute, Seattle WA. (Previously Henry Erlich, Ph.D.[3], Steven J. Mack, Ph.D., Anna Lisa Fear. Center for Genetics, Children's Hospital Oakland Research Institute.)

OGTT Laboratory: William E. Winter, M.D., David L. Pittman. UF Health Pathology Laboratories' (UFHPL) Endocrinology Laboratory, University of Florida, Gainesville, Florida, USA. (Previously Santica M. Marcovina, Ph.D., Sc.D., Andrew N. Hoofnagle, M.D., Ph.D., Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington.)

Repository: Sandra Ke, Niveen Mulholland, Ph.D. NIDDK Biosample Repository at Fisher BioServices.

Other contributors: Thomas Briese, Ph.D.[6], Columbia University. Todd Brusko, Ph.D.[5], University of Florida. Suzanne Bennett Johnson, Ph.D.[8,11], Florida State University. Eoin McKinney, Ph.D.[5], University of Cambridge. Tomi Pastinen, M.D., Ph.D.[5], The Children's Mercy Hospital. Eric Triplett, Ph.D.[6], University of Florida.

Committees:

[1]Ancillary Studies, [2]Diet, [3]Genetics, [4]Human Subjects/Publicity/Publications, [5]Immune Markers, [6]Infectious Agents, [7]Laboratory Implementation, [8]Psychosocial, [9]Quality Assurance, [10]Steering, [11]Study Coordinators, [12]Celiac Disease, [13]Clinical Implementation.

References

1. Sardinha LB, Andersen LB, Anderssen SA et al. Objectively measured time spent sedentary is associated with insulin resistance independent of overall and central body fat in 9-to-10-year-old Portuguese children. Diabetes Care 2008;31(3):569–575. [PubMed: 18070991]

2. Carson V, Ridgers N, Howard B et al. Light-intensity physical activity and cardiometabolic markers in US adolescents. PLOS ONE 2013;8(8):e71417. [PubMed: 23951157]

3. Haapala EA, Wiklund P, Lintu N et al. Cardiorespiratory fitness, physical activity, and insulin resistance in children. Med Sci Sports Exerc 2020;52(5):1144–1152. [PubMed: 31764464]

4. Kondakis K, Kondakis M, Androutsos O et al. Cardiorespiratory fitness is associated with body composition and insulin resistance in European adolescents: HELENA study. J Sports Med Phys Fitness 2020;60(10):1349–1357. [PubMed: 32608216]

5. Balkau B, Mhamdi L, Oppert JM et al. Physical activity and insulin sensitivity: The RISC study. Diabetes 2008;57:2613–2618. [PubMed: 18591396]

6. American Diabetes Association. Prevention or delay of type 2 diabetes: Standards of medical care in diabetes – 2021. Diabetes Care 2021;44(Suppl. 1):S34–S39. [PubMed: 33298414]

7. American Diabetes Association. Facilitating behavior change and well-being to improve health outcomes: Standards of medical care in diabetes – 2021. Diabetes Care 2021;44(Suppl. 1):S53–S72. [PubMed: 33298416]

8. Dahlquist G. Can we slow the rising incidence of childhood-onset autoimmune diabetes? The overload hypothesis. Diabetologia 2006;49:20–24. [PubMed: 16362279]

9. Helminen O, Aspholm S, Pokka T, Honen J, Simell O, Veijola R, Knip M. OGTT and random plasma glucose in the prediction of type 1 diabetes and time to diagnosis. Diabetologia 2015;58:1787–1796 [PubMed: 25985749]

10. Steck AK, Dong F, Frohnert BI et al. Predicting progression to diabetes in islet autoantibody positive children. J Autoimmun 2018;90:59–63. [PubMed: 29395739]

11. Simmons KM, Sosenko JM, Warnock M et al. One-hour oral glucose tolerance tests for the prediction and diagnostic surveillance of type 1 diabetes. J Clin End Metab 2020;105(11):e4094–e4101.

12. Ungethum K, Jolink M, Hippich M et al. Physical activity is associated with lower insulin and C-peptide during glucose challenge in children and adolescents with a family background of diabetes. Diabet Med.. 2019;36:366–375. [PubMed: 30242901]

13. TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) study: Study design. Pediatr Diabetes 2007;8:286–298. [PubMed: 17850472]

14. TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) study. Ann N Y Acad Sci 2008;1150:1–13.

15. Rewers M, Hyoty H, Lernmark A et al. The Environmental Determinants of Diabetes in the Young (TEDDY) Study: 2018 update. Curr Diab Rep 2019;18(12):136.

16. Krischer JP, Lynch KF, Lernmark A et al. Genetic and environmental interactions modify the risk of diabetes-related autoimmunity by 6 years of age: The TEDDY study. Diabetes Care 2017;40(9):1194–1202. [PubMed: 28646072]

17. Trost SG, Pate RR, Sallis JF et al. Age and gender differences in objectively-measured physical activity in youth. Med Sci Sports Exercise 2002;34(2):350–355.

18. Pate RR, Almeida MJ, McIver KL, Pfeiffer KA, Dowda M. Validation and calibration of an accelerometer in preschool children. Obesity 2006;14(11):2000–2006. [PubMed: 17135617]

19. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27(6):1487–1495. [PubMed: 15161807]

20. Leighton E, Sainsbury CAR, Jones GC. A practical review of C-peptide testing in diabetes. Diabetes Ther 2017;8:475–487. [PubMed: 28484968]

21. Frithloff-Bojsoe C, Lund MAV, Kloppenborg JT, et al. Glucose metabolism in children and adolescents: Population-based reference values and comparisons to children and adolescents enrolled in obesity treatment. Pediatric Diabetes 2019;20:538–548. [PubMed: 31074070]

22. American Diabetes Association. Classification and diagnosis of diabetes: Standards of medical care in Diabetes—2021. Diabetes Care 2021;44(Supplement 1):S15–S33. [PubMed: 33298413]

23. Brage S, Wedderkopp N, Ekelund U, Franks PW, Wareham NJ, Andersen LB, Froberg K. Objectively measured physical activity correlates with indices of insulin resistance in Danish children. The European Youth Heart Study (EYHS). Int J Obesity 2004;28:1503–1508.

24. Brage S, Wedderkopp N, Ekelund U, Franks PW, Wareham NJ, Andersen LB, Froberg K. Features of metabolic syndrome are associated with objectively measured physical activity and fitness in Danish children. The European Youth Heart Study (EYHS). Diabetes Care 2004;27(9):2141–2148. [PubMed: 15333475]

25. Krekoukia M, Nassis GP, Psarra G, Skenderi K, Chrousos GP, Sidossis LS. Elevated total and central adiposity and low physical activity are associated with insulin resistance in children. Metab Clin Exper 2007;56:206–213. [PubMed: 17224334]

26. Alhassan S, Robinson TN. Objectively measured physical activity and cardiovascular disease risk factors in African American girls. Ethn Dis 2008;18:421–426. [PubMed: 19157245]

27. Jago R, Wedderkopp N, Kristensen PL, Moller NC, Andersen LB, Cooper AR, Froberg K. Six year change in youth physical activity and effect on fasting insulin and HOMA-IR. J Preventive Med 2008;35(6):554–560.

28. Ekelund U, Luan J, Sherar L et al. Association of moderate to vigorous physical activity and sedentary time with cardiometabolic risk factors in children and adolescents. JAMA 2012;307(7):704–712. [PubMed: 22337681]

29. Bailey DP, Boddy LM, Savory LA, Denton SJ, Kerr CJ. Choice of activity-intensity classification thresholds impacts upon accelerometer-assessed physical activity-health relationships in children. PLOS ONE 2013;8(2)e57101. [PubMed: 23441234]

30. Strizich G, Kaplan RC, Stores-Alvarez D et al. Objectively measured sedentary behavior, physical activity, and cardiometabolic risk in Hispanic youth: Hispanic Community Health Study/Study of Latino Youth. J Clin Endocrinol Metab 2018;103(9):3289–3298. [PubMed: 29947786]

31. Carson V, Tremblay MS, Chaput JP, McGregor D, Chastin S. Compositional analyses of the associations between sedentary time, different intensities of physical activity, and cardiometabolic biomarkers among children and youth from the United States. PLOS ONE 2019;14(7):e0220009. [PubMed: 31329609]

32. Kehoe SH, Krishnaveni GV, Veena S et al. Active children are less adipose and insulin resistant in early adolescence; evidence from the Mysore Parthenon Cohort. BMC Pediatrics 2019;19:503. [PubMed: 31849318]

33. Leighton E, Sainsbury CAR, Jones GC. A practical review of C-peptide testing in diabetes. Diabetes Ther 2017;8:475–487. [PubMed: 28484968]

34. Basukala P, Jha B, Yadav BK, Shresha PK. Determination of insulin resistance and beta-cell function using homeostatic model assessment in type 2 diabetic patients at diagnosis. J Diabetes Metab 2018;9:790.

35. Troiano RP, Berrigan D, Dodd KW, Masse LC, Tilert T, McDowell M. Physical Activity in the United States measured by accelerometer. Med Sci Sports Exerc 2008;40(1):181–188. [PubMed: 18091006]

36. Xu P, Qian X, Shatz D, Cuthbertson D, Krischer JP, DPT-1 Study Group. Distribution of C-peptide and its determinants in North American children at risk for type 1 diabetes. Diabetes Care 2014;37:1959–1965. [PubMed: 24760262]

Figure 1a.

The Association of Low (30 min) and High (120 min) Moderate+Vigorous Physical Activity (mod+vig PA) to Glucose AUC for Children with Short (1 year) versus Long (5 years) Duration of Multiple Autoantibody Positivity

Figure estimates are based on the regression equation for Glucose AUC provided in Table 4. The remaining covariates are held constant for illustration purposes as follows: Country = US; Sex = female; HLA = NOT DR3/4; BMIz = 0; Age = 8; Accelerometer wear time = 900 minutes

Figure 1b.

The Association of Low (30 min) and High (120 min) Moderate+Vigorous Physical Activity (mod+vig PA) to C-peptide AUC for Children with Short (1 year) versus Long (5 years) Duration of Multiple Autoantibody Positivity

Figure estimates are based on the regression equation for C-peptide AUC provided in Table 5. The remaining covariates are held constant for illustration purposes as follows: Country = US; Sex = female; HLA = NOT DR3/4; BMIz = 0; Age = 8; Accelerometer wear time = 900 minutes

Figure 2.
The Association of Low (30 min) and High (120 min) Moderate+Vigorous Physical Activity (mod+vig PA) to C-peptide AUC for Children at 5 and 10 Years of Age

Figure estimates are based on the regression equation for C-peptide AUC provided in Table 5. The remaining covariates are held constant for illustration purposes as follows: Country = US; Sex = female; HLA = NOT DR3/4; BMIz = 0; Duration of Multiple Autoantibodies = 3; Accelerometer wear time = 900 minutes

Table 1.

Characteristics of Multiple Autoantibody Study Sample [*]

	1 OGTT (N = 340)	1 OGTT Plus 1 PA Measurement (N = 209)
Country		
United States	116 (34%)	69 (33%)
Finland	89 (26%)	52 (25%)
Germany	16 (5%)	12 (6%)
Sweden	119 (35%)	76 (36%)
Sex		
Female	141 (42%)	78 (37%)
Male	199 (58%)	131 (63%)
HLA		
DR3/4	177 (52%)	106 (51%)
DR4/4	82 (24%)	49 (23%)
DR4/8	45 (13%)	33 (16%)
DR3/3	28 (8%)	14 (7%)
Other	8 (2%)	7 (3%)
BMIz score at first OGTT/OGTT + PA assessment		
Mean (SD)	0.2 (1.1)	0.1 (1.1)
Median	0.3	0.2
Range	−3.4–2.5	−3.3–2.4
Age at first OGTT/OGTT + PA assessment (years)		
Mean (SD)	6.9 (2.3)	7.5 (2.3)
Median	5.8	7.1
Range	4.7-14.5	4.9–14.1
Age became persistent confirmed multiple autoantibody positive (years)		
Mean (SD)	5.3 (3.2)	4.9 (2.9)
Median	4.5	4.0
Range	0.5 –14.0	0.5–13.0
Duration of multiple autoantibody positivity at first OGGT/OGTT+PA assessment (years)		
Mean (SD)	1.6 (1.5)	2.6 (2.0)
Median	1.0	2.2
Range	0-6.7	0-9.3

OGGT = Oral Glucose Tolerance Test

PA = physical activity

[*] study sample was restricted to multiple autoantibody children at or after the 5- year assessment because physical activity assessment was started at the 5- year assessment window

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2.

Physical Activity and Study Outcome Measures at First Physical Activity Assessment Associated with an OGTT

Physical Activity (average minutes per day)	N	Mean (SD)	Range
Wear Time	209	1032 (162)	643-1328
Sedentary	209	568 (151)	213-913
Light	209	363 (55)	209-533
Moderate	209	89 (43)	12-231
Vigorous	209	12 (9)	0-45
Moderate+Vigorous	209	101 (49)	12-261
Study Outcomes			
Fasting Glucose mg/dL	209	88 (10)	60-128
120-minute Glucose mg/dL	200	112 (32)	47-252
Glucose AUC mg/dl	200	105 (23)	61-227
Hemoglobin A1	197	5.27 (0.29)	4.7-6.4
Fasting insulin mcU/ml	196	4.46 (2.71)	0.5-14.3
HOMA-IR	196	1.00 (0.65)	0.08-3.50
Fasting C-peptide ng/ml	197	0.99 (0.52)	0.06-3.93
120-minute C-peptide ng/ml	117	4.16 (1.98)	0.98-12.34
C-peptide AUC ng/ml	114	3.12 (1.78)	0.94-10.32

Table 3.

Correlations Between Study Outcome Measures At First Physical Activity Assessment Associated with an OGTT

Study Outcome	Fasting Glucose	120 Minute Glucose	Glucose AUC	HbA1c	Fasting Insulin	HOMA-IR	Fasting C-peptide	120-minute C-peptide
120-minute Glucose	0.16							
Glucose AUC	0.39 **	0.82 **						
HbA1c	0.29 **	0.44 **	0.42 **					
Fasting Insulin	0.45 **	−0.04	0.22 *	0.01				
HOMA-IR	0.55 **	−0.01	0.26 **	0.05	0.99 **			
Fasting C-peptide	0.41 **	−0.01	0.20 *	0.05	0.76 **	0.76 **		
120-minute C-peptide	0.25 *	0.35 **	0.46 **	0.00	0.67 **	0.65 **	0.62 **	
C-peptide AUC	0.26 *	0.24 *	0.55 **	−0.04	0.67 **	0.66 **	0.66 **	0.90 **

*
p < 0.01

**
p < 0.001

Table 4.

Linear Mixed Model Results for Moderate+Vigorous Physical Activity Associations with Glucose-Related Study Outcomes.

	Fasting Glucose (n = 209)	120 Min Glucose (n = 206)	Glucose AUC (n = 206)	HbA1c (n = 202)
	B (SE) p value	*B* (SE) p value	*B* (SE) p value	*B* (SE) p value
Intercept	76.1 (4.4) <0.001	86.7 (17.4) <0.001	54.4 (12.2) <0.001	5.1 (0.1) <0.001
Country (Ref = USA)	0.002	0.324	0.421	0.135
Finland	3.6 (1.5)	−3.8 (5.8)	−2.5 (4.0)	0.076 (0.051)
Germany	−6.0 (2.6)	−18.3 (9.9)	−11.6 (7.0)	0.121 (0.099)
Sweden	2.0 (1.4)	−4.1 (5.2)	−2.6 (3.7)	0.102 (0.046)
Sex (Ref = Female)	1.2 (1.2) 0.338	−2.4 (4.7) 0.613	−0.3 (3.4) 0.918	−0.039 (0.041) 0.351
HLA (Ref = NOT DR3/4)	1.6 (1.1) 0.172	4.7 (4.3) 0.287	3.2 (3.4) 0.302	0.045 (0.039) 0.244
BMIz score	1.7 (0.4) <0.001	1.5 (1.5) 0.330	0.7 (1.1) 0.500	0.005 (0.010) 0.631
Child Age	1.0 (0.4) 0.016	1.2 (1.6) 0.448	4.9 (1.2) <0.001	0.008 (0.012) 0.501
Duration of Multiple Autoantibody Positivity (MA+)	0.9 (0.4) 0.011	5.9 (1.5) <0.001	4.2 (1.1) <0.001	0.051 (0.012) <0.001
Accelerometer Wear Time	−0.00 (0.00) 0.639	0.01 (0.01) 0.421	0.01 (0.01) 0.399	−0.00 (0.00) 0.958
Moderate+Vigorous Physical Activity (mod+vig PA)	−0.00 (0.03) 0.930	0.12 (0.10) 0.258	0.15 (0.07) 0.031	−0.00 (0.00) 0.640
Mod+vig PA X Age	0.004 (0.004) 0.311	−0.10 (0.016) 0.535	−0.018 (0.012) 0.127	0.00 (0.00) 0.963
Mod+vig PA X Duration of MA+	−0.009 (0.004) 0.035	−0.035 (0.016) 0.026	−0.023 (0.011) 0.041	0.00 (0.00) 0.972

n=number of subjects in analysis, *B* represents the estimate from the model and SE represents its estimated standard error.

Table 5.

Linear Mixed Model Results for Moderate+Vigorous Physical Activity Associations with Insulin-Related Study Outcomes.

	Fasting Insulin mcU/ml X 100 (n= 201)	HOMA-IR (n= 201)	Fasting C-peptide ng/ml X 100 (n=202)	120-min C-peptide ng/ml X 100 (n=164)	C-peptide AUC X 100 (n=162)
	B (SE) p value	*B* (SE) p value	*B* (SE) p value	*B* (SE) p value	*B* (SE) p value
Intercept	−36.1 (119.6) 0.774	−0.28 (0.31) 0.359	4.3 (19.0) 0.819	192.7 (80.4) 0.017	−69.9 (62.6) 0.254
Country (Ref = USA)	0.148	0.071	0.652	0.052	0.147
Finland	50.7(34.4)	0.15 (0.09)	−5.6 (5.7)	−42.0 (26.0)	−34.6 (20.7)
Germany	−78.6 (59.6)	−0.22 (0.15)	−5.6 (9.8)	−81.6 (48.8)	−37.7 (38.7)
Sweden	20.0 (32.8)	0.06 (0.08)	−6.3 (5.4)	−63.3 (24.3)	−42.9 (19.5)
Sex (Ref = Female)	−17.1 (29.4) 0.561	−0.03 (0.07) 0.726	−5.5 (4.8) 0.255	−17.0 (21.5) 0.430	−5.7 (17.2) 0.741
HLA (Ref = NOT DR3/4)	−3.7 (26.7) 0.891	0.01 (0.07) 0.902	−2.3 (4.4) 0.596	3.6 (20.0) 0.858	−2.0 (16.0) 0.899
BMIz score	73.7 (10.2) <0.001	0.19 (0.03) <0.001	10.9 (1.6) <0.001	19.7 (6.6) 0.003	17.2 (5.1) <0.001
Child Age	71.3 (11.8) <0.001	0.18 (0.03) <0.001	15.8 (1.9) <0.001	43.3 (8.0) < 0.001	62.1 (6.3) <0.001
Duration of Multiple Autoantibody Positivity (MA+)	−13.4 (10.7) 0.212	−0.02 (0.03) 0.399	−4.5 (1.7) 0.009	−24.3 (7.1) <0.001	−21.3 (5.6) <0.001
Accelerometer Wear Time	0.03 (0.07) 0.653	0.00 (0.00) 0.786	0.00 (0.01) 0.840	0.02 (0.05) 0.725	−0.01 (.04) 0.779
Moderate+Vigorous Physical Activity (mod+vig PA)	0.50 (0.75) 0.507	0.00 (0.00) 0.367	0.31 (0.12) 0.009	0.50 (0.51) 0.319	1.2 (0.4) 0.003
Mod+vig PA X Age	−0.16 (0.12) 0.177	−0.00 (0.00) 0.182	−0.06 (0.02) <0.001	−0.21 (0.08) 0.006	−0.3 (0.06) <0.001
Mod+vig PA X Duration of MA+	0.02 (0.12) 0.849	−0.00 (0.00) 0.969	0.03 (0.02) 0.162	0.18 (0.08) 0.020	0.2 (0.06) 0.002

n=number of subjects in analysis, *B* represents the estimate from the model and SE represents its estimated standard error